STAMFORD, Conn., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of ...
Uremic pruritus is a debilitating symptom frequently encountered in individuals with chronic kidney disease (CKD), particularly those receiving haemodialysis. This condition, characterised by ...
Cara Therapeutics is developing an oral formulation for pruritus associated with various conditions after FDA-approved intravenous difelikefalin for ESRD patients. Although the primary endpoint was ...
Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Cara Therapeutics, Inc. (Nasdaq: CARA) today announced that the European Commission has granted marketing authorization to Kapruvia® ...
Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Cara Therapeutics, Inc. (Nasdaq: CARA) today announced that the European Medicines Agency’s (EMA) CHMP has recommended approval of Kapruvia® ...
Preliminary trial findings suggest transdermal cannabis may help ease pruritus-related itching in patients undergoing hemodialysis. Cannabis cream relieved itching symptoms over the short-term in a ...
Work at Escient Pharmaceuticals Inc. has led to the discovery of novel Mas-related G protein-coupled receptor member X4 (MRGPRX4) antagonists as potential therapeutic candidates for the treatment of ...
- FDA approval based on MARCH Phase 3 study with highly statistically significant (p<0.0001) reduction in pruritus severity between LIVMARLI vs. placebo FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum ...
Cara Therapeutics reported a decrease in cash, cash equivalents, and marketable securities, raising concerns about its financial position. The company's stock value has dropped by 60% since ...
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that the U.S. Food and Drug Administration (FDA) has extended the review of the Supplemental New Drug ...
Treatments for uremic bleeding target the various factors that seem to have a role in platelet dysfunction. Interventions can exert acute (within 6 h) or delayed (within several weeks) effects, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results